Nothing Special   »   [go: up one dir, main page]

EP1096927A4 - Composition for treatment of stress - Google Patents

Composition for treatment of stress

Info

Publication number
EP1096927A4
EP1096927A4 EP99934107A EP99934107A EP1096927A4 EP 1096927 A4 EP1096927 A4 EP 1096927A4 EP 99934107 A EP99934107 A EP 99934107A EP 99934107 A EP99934107 A EP 99934107A EP 1096927 A4 EP1096927 A4 EP 1096927A4
Authority
EP
European Patent Office
Prior art keywords
stress
treatment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99934107A
Other languages
German (de)
French (fr)
Other versions
EP1096927A1 (en
Inventor
Judith J Wurtman
Richard J Wurtman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of EP1096927A1 publication Critical patent/EP1096927A1/en
Publication of EP1096927A4 publication Critical patent/EP1096927A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99934107A 1998-07-16 1999-07-16 Composition for treatment of stress Withdrawn EP1096927A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9301398P 1998-07-16 1998-07-16
US93013P 1998-07-16
PCT/US1999/016153 WO2000003701A1 (en) 1998-07-16 1999-07-16 Composition for treatment of stress

Publications (2)

Publication Number Publication Date
EP1096927A1 EP1096927A1 (en) 2001-05-09
EP1096927A4 true EP1096927A4 (en) 2002-09-04

Family

ID=22236330

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99934107A Withdrawn EP1096927A4 (en) 1998-07-16 1999-07-16 Composition for treatment of stress

Country Status (4)

Country Link
EP (1) EP1096927A4 (en)
JP (1) JP2002520353A (en)
CA (1) CA2337507A1 (en)
WO (1) WO2000003701A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (en) 1999-07-08 2002-06-12 Lundbeck & Co As H TREATMENT OF NEUROTIC DISORDERS
WO2003082286A1 (en) * 2002-04-03 2003-10-09 Chemon Inc. Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same
CN1662231A (en) * 2002-04-24 2005-08-31 柏树生物科学公司 Prevention and treatment of functional somatic disorders, including stress-related disorders
RU2617512C1 (en) 2015-10-23 2017-04-25 Общество с ограниченной ответственностью "Нормофарм" Means with antistress, anxiolytic and antidepressant activity and composition based thereon
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3955918A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6147417A (en) * 1984-08-11 1986-03-07 Kanebo Shokuhin Kk Tranquilizing chewing gum
SU1593659A1 (en) * 1983-12-29 1990-09-23 Московская ветеринарная академия им.К.И.Скрябина Method of preventing stress of chickens
WO1993016695A1 (en) * 1992-02-21 1993-09-02 Ciba-Geigy Ag Brofaromine as an agent for treating post-traumatic stress
FR2710916A1 (en) * 1993-10-04 1995-04-14 Pasteur Institut Compounds of peptide nature having a serotoninergic response-modulating activity, diagnostic and therapeutic applications
EP0654264A1 (en) * 1993-11-24 1995-05-24 Eli Lilly And Company Treatment of incontinence with venlafaxine or an aryloxy propanamine compound
US5502080A (en) * 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
JPH0940648A (en) * 1995-08-02 1997-02-10 Yamanouchi Pharmaceut Co Ltd New 8-(2-aminoalkoxy)quinoline derivative

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
DK1738753T3 (en) * 1993-06-28 2008-08-11 Wyeth Corp New treatments using phenethylamine derivatives
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US5852020A (en) * 1996-11-22 1998-12-22 Bristol-Myers Squibb Company Nefazodone: use in treating post traumatic stress disorder

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1593659A1 (en) * 1983-12-29 1990-09-23 Московская ветеринарная академия им.К.И.Скрябина Method of preventing stress of chickens
JPS6147417A (en) * 1984-08-11 1986-03-07 Kanebo Shokuhin Kk Tranquilizing chewing gum
WO1993016695A1 (en) * 1992-02-21 1993-09-02 Ciba-Geigy Ag Brofaromine as an agent for treating post-traumatic stress
FR2710916A1 (en) * 1993-10-04 1995-04-14 Pasteur Institut Compounds of peptide nature having a serotoninergic response-modulating activity, diagnostic and therapeutic applications
EP0654264A1 (en) * 1993-11-24 1995-05-24 Eli Lilly And Company Treatment of incontinence with venlafaxine or an aryloxy propanamine compound
US5502080A (en) * 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
JPH0940648A (en) * 1995-08-02 1997-02-10 Yamanouchi Pharmaceut Co Ltd New 8-(2-aminoalkoxy)quinoline derivative

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
ACTA PSYCHIATRICA BELGICA., vol. 93, no. 3, 1993, pages 121 - 35 *
CLINICAL NEUROPHARMACOLOGY., vol. 11, no. S1, 1988, pages s86 - s89 *
DATABASE MEDLINE [online] 1988, BRINDLEY D N: "Metabolic and hormonal effects of dexfenfluramine on stress situations", XP002197785, Database accession no. NLM3180110 *
DATABASE MEDLINE [online] 1993, LEPINE ET AL: "Treatment of post-traumatic stress syndrome", XP002197786, Database accession no. NLM8030427 *
DATABASE WPI Section Ch Week 198616, Derwent World Patents Index; Class B02, AN 1986-103235, XP002197787 *
DATABASE WPI Section Ch Week 199132, Derwent World Patents Index; Class B06, AN 1991-236275, XP002197788 *
DATABASE WPI Section Ch Week 199716, Derwent World Patents Index; Class B02, AN 1997-175671, XP002197789 *
DAVIDSON J R T: "BIOLOGICAL THERAPIES FOR POSTTRAUMATIC STRESS DISORDER: AN OVERVIEW", JOURNAL OF CLINICAL PSYCHIATRY, XX, XX, vol. 58, no. 9, 1997, pages 29 - 32, XP000914294, ISSN: 0160-6689 *
FRIEDMAN M J: "DRUG TREATMENT FOR PTSD. ANSWERS AND QUESTIONS", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, US, June 1997 (1997-06-01), pages 359 - 371, XP000914298, ISSN: 0077-8923 *
GRAEFF FREDERICO G ET AL: "Role of 5-HT in stress, anxiety and depression.", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 54, no. 1, 1996, pages 129 - 141, XP002197781, ISSN: 0091-3057 *
MCKITTRICK CHRISTINA R ET AL: "Serotonin receptor binding in a colony model of chronic social stress.", BIOLOGICAL PSYCHIATRY, vol. 37, no. 6, 1995, pages 383 - 393, XP002197782, ISSN: 0006-3223 *
NEAL L A ET AL: "AN OPEN TRIAL OF MOCLOBEMIDE IN THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER", INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, CLINICAL NEUROSCIENCE PUBLISHERS, LONDON, GB, vol. 12, no. 4, July 1997 (1997-07-01), pages 231 - 237, XP000884760, ISSN: 0268-1315 *
PAPP MARIUSZ ET AL: "Pharmacological validation of the chronic mild stress model of depression.", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 296, no. 2, 1996, pages 129 - 136, XP002197783, ISSN: 0014-2999 *
See also references of WO0003701A1 *
ZETHOF THEO J J ET AL: "Stress-induced hyperthermia as a putative anxiety model.", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 294, no. 1, 1995, pages 125 - 135, XP002197784, ISSN: 0014-2999 *

Also Published As

Publication number Publication date
JP2002520353A (en) 2002-07-09
CA2337507A1 (en) 2000-01-27
WO2000003701A1 (en) 2000-01-27
EP1096927A1 (en) 2001-05-09

Similar Documents

Publication Publication Date Title
HUP0100765A3 (en) Composition for the treatment of halitosis
GB9824436D0 (en) Methods of treatment
HUP0103621A3 (en) Fentanyl composition for the treatment of acute pain
IL138129A (en) Composition for therapy of estrogen-associated disorders
AU2001233081A1 (en) Composition for treatment of stress
EP1117395A4 (en) Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same
EP1096927A4 (en) Composition for treatment of stress
IL139943A0 (en) Method of treatment
GB9904252D0 (en) Composition for the treatment of pain
GB9824893D0 (en) Novel method of treatment
GB9822681D0 (en) Method of treatment
PL346528A1 (en) Treatment of depression
EG24158A (en) Novel method of treatment
IL124878A0 (en) Composition for the treatment of seborrhea
GB9824791D0 (en) Novel methods of treatment
GB9824789D0 (en) Novel method of treatment
GB9824790D0 (en) Novel method of treatment
GB9824871D0 (en) Novel method of treatment
SI1135128T1 (en) Novel method of treatment
GB9800707D0 (en) Methods of treatment
GB9824208D0 (en) Methods of treatment
GB9822458D0 (en) Methods of treatment
GB9819673D0 (en) Composition for relieving stress
GB9818776D0 (en) Method of treatment
GB9808479D0 (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 45/08 A, 7A 61K 31/55 B, 7A 61P 9/12 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020718

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040202